Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $-29,160,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 800
- Avg volume
- 14,994
- Day's range
- $0.16 – $0.18
- Shares out
- —
- Stochastic %K
- 62%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- —
Company profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors...
Show more
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
- Phone
- 972 3 577 4115
- Website
- https://www.alphatau.com
- Address
- Kiryat HaMada St. 5, Jerusalem, Israel
Latest news
No headlines yet.
